ORIGINAL

Our experience of treatment of cribriform morular variant of papillary thyroid carcinoma; difference in clinicopathological features of FAP-associated and sporadic patients

Yasuhiro Ito¹⁾, Akira Miyauchi¹⁾, Hideki Ishikawa²⁾, Mitsuhiro Hirokawa³⁾, Takumi Kudo⁴⁾, Chisato Tomoda¹⁾ and Akihiro Miya¹⁾

¹⁾ Department of Surgery, Kuma Hospital, Kobe, Japan

²⁾ Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

³⁾ Department of Pathology, Kuma Hospital, Kobe, Japan

⁴⁾ Department of Internal Medicine, Kuma Hospital, Kobe, Japan

Abstract. Cribriform-morular variant (CMV) is a comparably rare histological subtype of papillary thyroid carcinoma (PTC). This can be associated with familial adenomatous polyposis (FAP) due to *APC* gene mutations. In this study, we investigated the difference in the biological characteristics between FAP-associated and sporadic CMV. Between 1991 and 2010, 32 patients with CMV were treated in Kuma Hospital. Thirty-one of these underwent initial surgery for CMV in Kuma Hospital. Twelve patients were FAP-associated and the remaining 19 were sporadic CMV. All patients were female. Tumors of FAP-associated CMV were more frequently multiple than those of sporadic CMV. Patient age and tumor size did not differ between the two groups. Of 12 FAP-associated CMV, 5 were detected by thyroid nodule (thyroid precedent group) and 7 were detected by FAP (polyposis precedent group) as an initial manifestation. Patient age was younger and tumor size was smaller in the polyposis group than in the thyroid nodule group. All patients lacked extrathyroid extension on intraoperative finding and were node-negative on pathological examination. To date, two patients with FAP-associated CMV who initially underwent hemithyroidectomy (one in Kuma Hospital and one in another hospital) showed recurrence to the remnant thyroid during follow-up. None of the patients showed recurrence to other regions or died of carcinoma. Taken together, CMV is considered an indolent disease in our series. FAP-associated CMV showed multiple tumors more frequently than sporadic CMV. Total thyroidectomy is recommended for FAP-associated CMV, but extensive lymph node dissection is not necessary.

Key words: Cribriform morular variant, Papillary thyroid carcinoma, FAP, Prognosis

PAPILLARY thyroid carcinoma (PTC) is the most common malignancy arising from thyroid follicular cells. There are many histological subtypes of PTC and some of them showed a different prognosis from conventional PTC. Cribriform-morular variant (CMV) is a rare subtype of PTC. Historically, in 1949, Crail first reported malignancies originating from the rectum, brain and the thyroid gland [1]. In 1968, the relation between familial adenomatous polyposis (FAP) and thyroid carcinoma was reported [2]. Furthermore, one

study showed that young women with FAP had approximately 160 times more risk of thyroid carcinoma than healthy people [3]. In 1994, Harach *et al.* demonstrated unique histological features of FAP-associated PTC such as a cribriform pattern and solid areas with a spindle cell component [4]. The *APC* gene located in the 5q21 region is strongly associated with FAP and individuals with *APC* mutations have almost 100% risk of developing colorectal carcinoma [5, 6], allowing us to conclude that this variant is significantly associated with *APC* mutations. Other studies have also reported FAP-associated CMV [7, 8], but CMV can occur also sporadically without any relation to colonic polyposis [8-10].

In 2004, we reported 7 patients with CMV [11]. Three

Received May 12, 2011; Accepted May 30, 2011 as EJ11-0022
Released online in J-STAGE as advance publication Jun. 14, 2011
Correspondence to: Yasuhiro Ito, M.D., Ph.D. Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, Kobe 650-0011, Japan. E-mail: ito01@kuma-h.or.jp

of these patients were FAP-associated CMV because they had FAP or a family history of colonic carcinoma involving *APC* gene mutations. The remaining 4 were sporadic and lacked *APC* gene mutations. However, primary lesions in all of these patients were detected by thyroid nodule as an initial manifestation. Recently, the relationship between CMV and FAP has been more widely understood and CMV has been detected during thyroid screening in FAP patients without complaint of thyroid nodule.

In this study, we investigated the biological characteristics of CMV in 32 patients. Thirty-one patients underwent initial surgery in Kuma Hospital. Twenty of these patients were FAP-associated and the remaining 19 were sporadic CMV. We investigated the difference in clinicopathological features between these two groups.

Patients and Methods

Between 1991 and 2010, 32 patients with PTC underwent surgery and pathologically diagnosed as CMV in Kuma Hospital, who were enrolled in this study. All patients were females and patient age ranged from 17 to 38 years (average 27 years). These 32 patients underwent ultrasound-guided fine needle aspiration biopsy (FNAB) and were cytologically diagnosed as having PTC. Sixteen (50%) were also diagnosed as or highly suspected of CMV based on cytological findings such as the presence of a morular component, peculiar nuclear clearing, absence of colloid in the background and immunocytochemistry finding such as nuclear and cytoplasmic localization of beta-catenin and high positivity of estrogen receptor (ER) [12, 13].

Thirty-one of these patients underwent initial surgery in Kuma Hospital. Twelve of these patients (31%) were FAP-associated CMV because they had one or more of the following three features; 1) colonic polyposis was detected on total colonoscopy before or after thyroid surgery; 2) presence of *APC* gene mutations; and 3) family history of colonic polyposis or colorectal carcinoma. CMV in 5 patients was detected by thyroid nodule based on patient complaints or findings on medical check-up as the initial event. These patients underwent total colonoscopy after thyroid surgery and were diagnosed as having polyposis. The remaining 7 underwent thyroid ultrasound for screening after the detection of FAP and were referred to our hospital because thyroid nodules were found. None of these

patients had complained of thyroid nodule prior to its detection. Nineteen patients (69%) were diagnosed as having sporadic CMV without any of the 3 features, which includes 3 patients who had no family history of colonic polyposis or colorectal carcinoma and rejected examination of colonic polyposis.

The extent of thyroidectomy for FAP-associated CMV was total thyroidectomy in 11 patients and hemithyroidectomy in 1 patient. That for sporadic CMV was total thyroidectomy in 9 patients and hemithyroidectomy in 10 patients. Completion total thyroidectomy was performed as the second surgery in one patient who underwent initial surgery at another hospital. All patients underwent central node dissection. Three patients with FAP-associated CMV and 8 with sporadic CMV also underwent modified radical neck dissection (MND). All patients were diagnosed as having CMV on postoperative pathological examination based on morphological findings such as cribriform pattern, morular component, lack of colloid, peculiar nuclear clearing and immunohistochemical findings of beta-catenin, ER and progesterone receptor (PgR) [4, 8, 9, 14].

Our series included 7 patients reported in our previous study who underwent *APC* gene mutation analysis [11]. The *APC* gene mutation was not analyzed in other patients.

None of the patients in our series underwent radioactive iodine (RAI) ablation or RAI therapy. After surgery, all patients were followed by ultrasound at least once per year. The follow-up periods of these 31 patients ranged from 4 to 217 months (average 59 months).

Fisher's exact test and Mann-Whitney U test were adopted for comparing variables. *p* values less than 0.05 were considered significant.

Results

Of 32 patients with CMV, 31 underwent initial surgery in Kuma Hospital. Twelve of these patients (39%) were diagnosed as having FAP-associated CMV because they had one or more of the following three features as indicate above, and the remaining 19 (61%) demonstrated sporadic CMV. Nine patients with FAP-associated CMV (75%) and 7 with sporadic CMV (37%) were preoperatively diagnosed as having or highly suspected of CMV based on the cytological findings indicated above. Multinodular goiter and euthyroid Graves' disease were detected in 3 patients and 1 patient with sporadic CMV, respectively. No

Table 1 Comparison of multiplicity on ultrasound for FAP-associated and sporadic CMV

	Multiplicity (%)		
	Solitary	Multiple	Total
FAP-associated CMV	3 (25)	9 (75)	12
Sporadic CMV	19 (100)	0	19
Total	22	9	31

 $p = 0.00001$ **Table 2** Comparison of multiplicity on pathological examination for FAP-associated and sporadic CMV

	Multiplicity (%)		
	Solitary	Multiple	Total
FAP-associated CMV	2 (17)	10 (83)	12
Sporadic CMV	17 (89)	2 (11)	19
Total	19	12	31

 $p = 0.0005$ **Fig. 1** Comparison of age of FAP-associated patients between the thyroid precedent group and polyposis precedent group. **Fig. 2** Comparison of tumor size of FAP-associated patients between the thyroid precedent group and polyposis precedent group.

other thyroid comorbidities can be observed in FAP-associated CMV.

We compared the clinicopathological features between the two groups. Tumor size (1.79 ± 1.15 cm vs 2.38 ± 0.70 cm) and patient age (26.3 ± 3.7 years vs 26.8 ± 6.6 years) did not significantly differ between FAP-associated and sporadic CMV. Nine of 12 patients (75%) with FAP-associated CMV but none of the sporadic CMV were evaluated as multiple on preoperative ultrasound ($p = 0.00001$) (Table 1). On pathological examination, 10 patients with FAP-associated CMV (83%) and 2 with sporadic CMV (11%) showed multi-

plicity ($p = 0.00005$) (Table 2).

Diagnosis of CMV in 5 of 12 FAP-associated CMV patients (42%) was based on finding a thyroid nodule (thyroid precedent group) and that in 7 (58%) was based on FAP (polyposis precedent group) as the initial manifestation. Although not significantly different, patient age in the thyroid precedent group (28.4 ± 3.4 years) tended to be older than that in the polyposis precedent group (24.7 ± 3.5 years) ($p = 0.09511$) (Fig. 1). Tumor size in the thyroid precedent group (2.6 ± 1.0 cm) was significantly larger than that in the polyposis precedent group (1.2 ± 0.9 cm) ($p = 0.02627$) (Fig. 2).

None of the patients showed extrathyroid extension corresponding to T3 or T4 or lymph node metastasis corresponding to N1 in the UICC TNM classification [13] based on preoperative and intraoperative findings. On pathological examination, all patients were node-negative. To date, two patients with FAP-associated CMV, who underwent hemithyroidectomy at the initial surgery (one in Kuma hospital and one in another hospital) and were diagnosed as having polyposis thereafter, showed recurrence to the remnant thyroid 86 and 90 months after initial surgery, respectively. These patients underwent a second surgery and further recurrence has not been detected to date. Furthermore, one patient died of colorectal carcinoma 64 months after thyroid surgery and one died of lung suppuration unrelated to PTC or colorectal carcinoma 28 months after surgery. The other patients have survived without any evidence of PTC recurrence to date.

Discussion

There are two types of CMV etiology; FAP-associated and sporadic. Furthermore, there are two initial manifestations of FAP-associated CMV detection: thyroid nodule and FAP. We compared clinico-pathological features between the two groups.

CMV can be diagnosed by preoperative cytological findings [12]. In our series, 75% of FAP-associated CMV and 37% of sporadic CMV were diagnosed as or highly suspected of CMV on cytology. The higher incidence in FAP-associated CMV is definitely because we ordered immunocytochemistry for beta-catenin and ER for patients who were known to have FAP.

Since it is well-known that CMV can be associated with FAP, screening of colonic polyposis by total colonoscopy should be recommended for patients who were diagnosed as having CMV. We demonstrated that FAP-associated CMV showed multiple tumors more frequently than sporadic CMV both on preoperative imaging studies and on pathological examination, indicating that the presence of FAP is highly suspected

especially for patients with multiple CMV. In the subset of FAP-associated CMV, patients in the polyposis precedent group were younger and had smaller tumors than those in the thyroid precedent group. It is therefore suggested that thyroid screening for FAP patients contributes to early detection of CMV, even before patients become aware of thyroid nodule.

All patients in our series were node-negative and lacked extrathyroid extension. Furthermore, none of these patients died of carcinoma. These findings indicate that CMV normally shows an indolent character regardless of whether it is FAP-associated, which was not discrepant with previous studies [8, 9, 10, 16]. There is one report of CMV in an older (42 years) male patient who died of carcinoma only 17 months after surgery, but this seems atypical because neuroendocrine differentiation and a poorly differentiated component were present [17]. To date, however, 2 patients who underwent hemithyroidectomy for FAP-associated CMV recurred to the remnant thyroid during follow-up. Based on these findings, total thyroidectomy is recommended for CMV patients with multiple carcinoma lesions, a family history of colonic polyposis or colorectal carcinoma or diagnosed as having colonic polyposis before thyroid surgery. In contrast, none of the sporadic patients showed recurrence to the remnant thyroid, even though they underwent hemithyroidectomy, indicating that total thyroidectomy may not be mandatory for such patients. In our department, prophylactic MND has been performed for PTC patients having tumor larger than 3 cm, because these patients are likely to develop recurrence in regional lymph nodes [18]. However, such an extensive prophylactic node dissection is not needed for patients who were preoperatively diagnosed as having CMV.

Taken together, we showed that FAP-associated CMV showed multiple tumors more frequently than sporadic CMV. Total thyroidectomy is recommended at least for CMV patients associated with FAP, but extensive lymph node dissection is not necessary.

References

1. Crail HW (1949) Multiple primary malignancies arising in the rectum, brain, and the thyroid: report of a case. *U S Nav Med Bull* 49: 123-128.
2. Camiel MR, Mule JE, Alexander LL, Benninghoff DL (1968) Association of thyroid carcinoma with Gardner's syndrome in siblings. *N Engl J Med* 278: 1056-1058.
3. Plail RO, Bussey HJ, Glazer G, Thompsom JP (1987) Adenomatous polyposis: an association with carcinoma

- of the thyroid. *Br J Surg* 74: 377-380.
4. Harach HR, Williams GT, Williams ED (1994) Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. *Histopathology* 25: 549-561.
 5. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spiro L, Robertson M (1991) Identification and characterization of the familial adenomatous polyposis coli. Gene. *Cell* 66: 589-600.
 6. Kinzler KW, Nibert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D (1991) Identification of FAP locus gene from chromosome 5q21. *Science* 253: 661-665.
 7. Cetta F, Pelizzo MR, Caria MC, Barbarisi A (1999) Genetics and clinicopathological findings in thyroid carcinomas associated with familial adenomatous polyposis. *Am J Pathol* 155: 7-9.
 8. Cameselle-Teijeiro J, Chan JK (1999) Cribriform-morular variant of papillary carcinoma: A distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? *Mod Pathol* 12: 400-411.
 9. Ng SB, Sittampalm K, Goh YH, Eu KW (2003) Cribriform-morular variant of papillary carcinoma: The sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma. A case report with clinical and molecular genetic correlation. *Pathology* 35: 42-46.
 10. Xu B, Yoshimoto K, Miyauchi A, Kuma S, Mizusawa N, Hirokawa M, Sano T (2003) Cribriform-morular variant of papillary thyroid carcinoma: A pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene. *J Pathol* 199: 58-67.
 11. Tomoda C, Miyauchi A, Uruno T, Takamura Y, Ito Y, Kobayashi K, Matsuzuka F, Kuma S, Kuma K, Kakudo K (2004) Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. *World J Surg* 28: 886-889.
 12. Hirokawa M, Maekawa M, Kuma S, Miyauchi A (2010) Cribriform-morular variant of papillary thyroid carcinoma-cytological and immunocytochemical findings of 18 cases. *Diag Cytopathol* 38: 890-896.
 13. Kuma S, Hirokawa M, Xu B, Miyauchi A, Kakudo K, Sano T (2004) Cribriform-morular variant of papillary thyroid carcinoma. Report of a case showing morules with peculiar nuclear clearing. *Acta Cytol* 48: 431-436.
 14. Kurihara K, Shimizu S, Chong J, Hishima T, Funata N, Kashiwagi H, Nagai H, Miyaki M, Fukayama M (2000) Nuclear localization of immunoreactive beta-catenin is specific to familial adenomatous polyposis in papillary thyroid carcinoma. *Jpn J Cancer Res* 91: 1100-1102.
 15. Sobin LH, Wittekind Ch., eds. (2002) UICC; TNM classification of malignant tumors, 6th ed. New York: Wiley-Liss.
 16. Perrier ND, van Heerden JA, Goellner JR, Williams ED, Gharib H, Marchesa P, Church JM, Fazio VW, Larson DR (1998) Thyroid cancer in patients with familial adenomatous polyposis. *World J Surg* 22: 738-742.
 17. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruiz-Ponte C, Soares P, Sobrinho-Simoes M (2009) Cribriform-morular variant of papillary thyroid carcinoma. Molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. *Am J Clin Pathol* 131: 134-142.
 18. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A (2007) Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. *World J Surg* 31: 2085-2091.